Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial

Zhang Li(Chongqing Academy of Chinese Materia Medica), Aie Xu(Third People's Hospital of Hangzhou), Wenli Feng, Jiang Meiying(Nanchang University), Rixin Chen(Nanchang University), Zhihong Xie(Beijing Hospital), Yunsheng Liang(Southern Medical University), Bingjiang Lin(Ningbo University Affiliated Hospital), Liming Wu(Hangzhou First People's Hospital), Xiaoping Pei(Southern Medical University), Kunpeng Bian(Nanyang Institute of Technology), Linfeng Li(Beijing Tongren Hospital), Guoqiang Zhang(Hebei Medical University), Mingyue Wang(Peking University), Lei Cao(Wuxi No.2 People's Hospital), Yanyan Feng(Shanghai Jiao Tong University), Litao Zhang(Tianjin University of Traditional Chinese Medicine), Wenlin Yang(Second Affiliated Hospital of Guangzhou Medical University), Zudong Meng(People's Hospital of Shiyan), Yingxia He(Flower Hospital), Chao Ji(Zhongshan Hospital of Xiamen University), D. Du(Five Prime Therapeutics (United States))
British Journal of Dermatology
September 17, 2025
Cited by 0


Related Papers